{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-000689","form_type":"8-K","ticker":"CING","cik":"0001862150","company_name":"Cingulate Inc.","filed_at":"2025-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.364639+00:00","generated_at":"2026-05-24T05:14:43.819125+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cingulate reports FY 2024 net loss $15.5M; cash runway extended to Q4 2025, NDA for CTx-1301 targeted mid-2025","bullets":["Cash and equivalents $12.2M (vs $52k Dec 2023); working capital improved to $7.5M from -$9.6M.","Net loss narrowed to $15.5M from $23.5M in 2023; R&D expenses fell to $9.4M from $15.5M.","Pre-NDA FDA meeting scheduled April 2, 2025; NDA submission for CTx-1301 targeted mid-2025.","Phase 3 pediatric safety data showed no serious TEAEs across nine clinical trials.","Raised $17.5M in capital in 2024 via public offering, warrant inducement, and promissory note."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-000689","json":"https://secwatch.observer/filing/0001641172-25-000689.json","markdown":"https://secwatch.observer/filing/0001641172-25-000689.md","text":"https://secwatch.observer/filing/0001641172-25-000689.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1862150/000164117225000689/0001641172-25-000689-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1862150/000164117225000689/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T05:14:43.819125+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}